Posted by Michael Wonder on 30 Nov 2023
Schedule of Pharmaceutical Benefits - 1 December 2023
1 December 2023 - The December 2023 issue of the Schedule of Pharmaceutical Benefits is out and now in effect.
The December issue of the Schedule includes a few major new/revised listings:
- Darolutamide (Nubeqa) - new indication
- Durvalumab (Imfinzi) - new indications x 2
- Essential amino acids formula with vitamins and minerals (EAA Supplement) - new formulation
- Nivolumab (Opdivo) - restriction change
- Pembrolizumab (Keytruda) - new indication
- Tofacitinib citrate (Xeljanz) - new indication
- Upadacitinib monohydrate (Rinvoq) - new indication
- Zoledronic acid monohydrate (Zoledronic Acid Accord) - new indication
